The Motley Fool··Lee SamahaNovo Nordisk's Sickle Cell Win Decimates Agios Stock 23% in Single Day
Agios Pharmaceuticals plunged 23% after Novo Nordisk's superior sickle cell drug trial results overshadowed Agios' failed mitapavit candidate, threatening its commercial viability.
NVOAGIOFDA approvalclinical trial results